Chattem R&D
This article was originally published in The Tan Sheet
Executive Summary
Donald Riker, PhD, named VP-R&D and chief scientific officer, replacing former R&D head Elaine Morefield, PhD, who left in July to pursue other interests. Riker brings almost 20 years experience in clinical-regulatory affairs, licensing and OTC product development at P&G and Richardson-Vicks, working on such brands as NyQuil, DayQuil, Vicks VapoRub and Formula 44. He has served as associate director and P&G Fellow at Procter's global healthcare facility in Mason, Ohio, since 1992. Chattem says creation of CSO post signals greater emphasis on R&D...
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.